3,3-dimethyl-2-oxo-glutaric acid | 112428-39-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: 3,3-dimethyl-2-oxo-glutaric acid
• 英文别名: 3,3-Dimethyl-2-oxo-glutarsaeure；3,3-dimethyl-2-oxoglutaric acid；3,3-Dimethyl-2-oxopentanedioic acid
• CAS: 112428-39-4
• 化学式: C₇H₁₀O₅
• 分子量: 174.153
• InChiKey: ZBCDQFRAXYLCLF-UHFFFAOYSA-N

物化性质

• 沸点：
  333.1±25.0 °C(Predicted)
• 密度：
  1.334±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  91.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3,3-dimethyl-2-oxo-glutaric acid 、 4-硝基苯肼 生成 3,3-dimethyl-2-(4-nitro-phenylhydrazono)-glutaric acid
  参考文献：
  名称：

  122.石竹烯。第二部分

  摘要：

  DOI：

  10.1039/jr9350000532
• 作为产物：
  描述：

  3,3-dimethyl-4-oxopentanoic acid 在 sodium hydroxide 、 potassium permanganate 、 sodium 作用下， 生成 3,3-dimethyl-2-oxo-glutaric acid
  参考文献：
  名称：

  Antibiotic

  摘要：

  该化合物由以下结构式表示：##STR1## 其中，R1代表氨基或通过氮原子连接的有机残基；R2代表羧基或由此衍生的基团；R3、R4、R5、R6、R7和R8各自独立地代表氢或有机残基，包括R5或R6与R7或R8形成化学键或环的情况；X代表氢、甲氧基或甲酰氨基；或其盐，可通过本方法制备，表现出优异的抗菌活性，并被用作抗菌剂。

  公开号：

  US04851422A1

文献信息

• Compositions for Targeted Delivery of siRNA
  申请人：Rozema David B.

  公开号：US20110207799A1

  公开（公告）日：2011-08-25

  The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.

  本发明涉及用于靶向递送RNA干扰（RNAi）多核苷酸至体内肝细胞的组合物。靶向RNAi多核苷酸与共靶向递送聚合物一起给予。递送聚合物提供膜穿透功能，用于将RNAi多核苷酸从细胞外运送到细胞内。可逆修饰为递送聚合物提供生理响应性。
• GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA
  申请人：Hadwiger Philipp

  公开号：US20120157509A1

  公开（公告）日：2012-06-21

  The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cell in vivo. The pharmacokinetic modulator improve in vivo targeting compared to the targeting ligand alone. Targeting ligand-pharmacokinetic modulator targeting moiety targeted RNAi polynucleotides can be administered in vivo alone or together with co-targeted delivery polymers.

  本发明涉及用于靶向递送RNA干扰（RNAi）多核苷酸至体内细胞的组合物。与单独的靶向配体相比，药代动力学调节剂改善了体内靶向。靶向配体-药代动力学调节剂靶向基团靶向的RNAi多核苷酸可以单独或与共靶向递送聚合物一起在体内给予。
• [EN] 1-AMIDO-4-PHENYL-4-BENZYLOXYMETHYL-PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS NEUROKININ-1(NK-1) ANTAGONISTS FOR THE TREATMENT OF EMESIS, DEPRESSION, ANXIETY AND COUGH<br/>[FR] DERIVES DE 1-AMIDO-4-PHENYL-4-BENZYLOXYMETHYL-PIPERIDINE ET COMPOSES ASSOCIES EN TANT QU'ANTAGONISTES DE LA NEUROKININE-1(NK-1) DANS LE TRAITEMENT DES VOMISSEMENTS, DE LA DEPRESSION, DE L'ANGOISSE ET DE LA TOUX
  申请人：SCHERING CORP

  公开号：WO2004004722A1

  公开（公告）日：2004-01-15

  Disclosed are NK1 antagonists having the formula: Also disclosed are uses of compounds of formula (I) for the manufacture of a medicament for treating a number of physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

  揭示了具有以下结构式的NK1拮抗剂：还揭示了利用结构式（I）化合物制备用于治疗多种生理紊乱、症状或疾病的药物，包括恶心、抑郁、焦虑和咳嗽。
• Novel methods for the delivery of polynucleotides to cells
  申请人：——

  公开号：US20030235916A1

  公开（公告）日：2003-12-25

  Process are described for the delivery of a polynucleotide to a cell. The process comprises forming a salt stable complex between the polynucleotide and a cationic surfactant. Ternary complexes are also made by associating an amphipathic compound with the binary complex. The resultant complexes are suitable for delivery of the polynucleotide to cells in vitro and in vivo.

  描述了将多核苷酸传递到细胞的过程。该过程包括在多核苷酸和阳离子表面活性剂之间形成一个盐稳定的复合物。三元复合物也可以通过将一个两性化合物与二元复合物结合而制备。所得的复合物适用于体外和体内向细胞传递多核苷酸。
• REVERSING THE UNDESIRABLE pH-PROFILE OF DOXORUBICIN VIA ACTIVATION OF A DISUBSTITUTED MALEAMIC ACID PRODRUG AT TUMOR ACIDITY
  申请人：The Research Foundation for The State University of new York

  公开号：US20210128592A1

  公开（公告）日：2021-05-06

  A pre-prodrug, comprising a drug, e.g., doxorubicin, which has off-target toxicity (e.g., cardiotoxicity) with respect to its antineoplastic activity, and an amine functionality of the drug incorporated into a disubstituted maleimide (DMI). The pre-prodrug may be linked to a targeting or de-targeting agent or a polar modulator, e.g., charged ligand, amino acid, peptide, etc., to increase therapeutic index. The pre-prodrug is hydrolyzed to the prodrug, having a disubstituted maleamic acid (DMA). A polar modulator such as glutamic acid prevents cellular uptake of the prodrug, but not the doxorubicin drug released from the prodrug after dissociation. The prodrug is pH sensitive, and below pH 7.0, tends to cleave to form free drug and cyclized maleic anhydride. Tumor environments tend to be more acidic, e.g., pH 6.8, than cardiac tissue, e.g., pH 7.4, and therefore the heart is spared while the drug is selectively released within a tumor.

  一种前前药，包括一种药物，例如阿霉素，其在抗肿瘤活性方面存在非靶向毒性（例如心脏毒性），以及药物的胺基功能并入二取代马来酰亚胺（DMI）中。前前药可以与靶向或去靶化剂或极性调节剂连接，例如带电配体、氨基酸、肽等，以增加治疗指数。前前药水解为前药，具有二取代马来酰胺（DMA）。极性调节剂如谷氨酸可防止前药的细胞摄取，但不影响前药解离后释放的阿霉素药物。前药对pH敏感，在pH 7.0以下，倾向于裂解形成游离药物和环化马来酸酐。肿瘤环境往往比心脏组织更酸性，例如pH 6.8，因此心脏得以保护，而药物选择性地在肿瘤内释放。